Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Enthesitis Related Arthritis (ERA) as defined by International League of Associations for Rheumatology (ILAR);~* Disease activity defined as at least 3 active joints and evidence of enthesitis in at least one location;~* Inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug and at least one disease modifying anti-rheumatic drug, either sulfasalazine or methotrexate.~Exclusion Criteria:~* Any ILAR Juvenile Idiopathic Arthritis (JIA) subtype other than ERA;~* Psoriasis or a history of psoriasis in the patient or first-degree relative;~* Presence of Immunoglobulin M (IgM) rheumatoid factor;~* Presence of systemic JIA;~* History of inflammatory bowel disease;~* previous biologic therapy including anti-tumor necrosis factor (anti-TNF) therapy with a potential impact on pediatric ERA;~* Infection(s) requiring treatment with IV anti-infectives within 30 days prior to Baseline or oral anti-infectives within 14 days prior to Baseline.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Double-blind Placebo EOW (Type: PLACEBO_COMPARATOR): Placebo for adalimumab every other week (eow) for 12 weeks.
- Double-blind Adalimumab EOW (Type: EXPERIMENTAL): Adalimumab (body surface area dosing 24 mg/m\^2 up to a maximum of 40 mg) every other week (eow) for 12 weeks.
- Open-label Adalimumab EOW (Type: EXPERIMENTAL): Adalimumab (body surface area dosing 24 mg/m\^2 up to a maximum of 40 mg) every other week (eow) for up to 192 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).